Efficacy of systemic therapy in breast cancer with CNS metastases: “Real-world” experience. Effect of CD4+PD-1+CXCR6+ T cells on the response of immune checkpoint inhibitor therapy in brain metastases ...
The FDA approved the intrathecal gene therapy onasemnogene abeparvovec (Itvisma) to treat spinal muscular atrophy (SMA) in adults and pediatric patients 2 years and older with a confirmed mutation in ...
Panelists discuss how intrathecal delivery of onasemnogene abeparvovec in the STEER study demonstrates statistically significant motor function improvements in older patients with SMA (ages 2-18 years ...
(Nanowerk News) Using nanoparticles administered directly into the cerebrospinal fluid (CSF), a research team has developed a treatment that may overcome significant challenges in treating a ...
If approved, Itvisma (intrathecal onasemnogene?abeparvovec) will be first and only gene replacement therapy for children two years and older, teens and adults with SMA in the European UnionItvisma dem ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results